Search Results - "Ros, Willeke"

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study by Chung, Hyun Cheol, Ros, Willeke, Delord, Jean-Pierre, Perets, Ruth, Italiano, Antoine, Shapira-Frommer, Ronnie, Manzuk, Lyudmila, Piha-Paul, Sarina A, Xu, Lei, Zeigenfuss, Susan, Pruitt, Scott K, Leary, Alexandra

“…KEYNOTE-158 ( ClinicalTrials.gov identifier: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of pembrolizumab in…”
Get full text

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies by Piha‐Paul, Sarina A., Oh, Do‐Youn, Ueno, Makoto, Malka, David, Chung, Hyun Cheol, Nagrial, Adnan, Kelley, Robin K., Ros, Willeke, Italiano, Antoine, Nakagawa, Kazuhiko, Rugo, Hope S., Braud, Filippo, Varga, Andrea Iolanda, Hansen, Aaron, Wang, Hui, Krishnan, Suba, Norwood, Kevin G., Doi, Toshihiko

“…We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE‐158 (NCT02628067; phase 2) and KEYNOTE‐028…”
Get full text

Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid by Pluim, Dick, Ros, Willeke, van Bussel, Mark T.J., Brandsma, Dieta, Beijnen, Jos H., Schellens, Jan H.M.

“…•Nivolumab and pembrolizumab levels in cerebrospinal fluid are much lower than in serum.•Validated enzyme-linked immunoassay can quantify those levels up to 2…”
Get full text

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges by Brummelen, Emilie M.J., Ros, Willeke, Wolbink, Gertjan, Beijnen, Jos H., Schellens, Jan H.M.

“…In oncology, an increasing number of targeted anticancer agents and immunotherapies are of biological origin. These biological drugs may trigger immune…”
Get full text

Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD‐1 Expression Levels and PD‐1 Receptor Occupancy by Nivolumab and Pembrolizumab by Pluim, Dick, Ros, Willeke, Miedema, Iris H. C., Beijnen, Jos H., Schellens, Jan H. M.

“…We report the development and validation of a 12 parameter immunofluorescence flow cytometry method for the sensitive determination of cell concentrations,…”
Get full text

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors by Hamid, Omid, Chiappori, Alberto A, Thompson, John A, Doi, Toshihiko, Hu-Lieskovan, Siwen, Eskens, Ferry A L M, Ros, Willeke, Diab, Adi, Spano, Jean-Philippe, Rizvi, Naiyer A, Wasser, Jeffrey S, Angevin, Eric, Ott, Patrick A, Forgie, Alison, Yang, Wenjing, Guo, Cen, Chou, Jeffrey, El-Khoueiry, Anthony B

“…BackgroundIvuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively. This…”
Get full text

Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158 by Chung, Hyun Cheol, Lopez-Martin, Jose A., Kao, Stephen Chuan-Hao, Miller, Wilson H., Ros, Willeke, Gao, Bo, Marabelle, Aurelien, Gottfried, Maya, Zer, Alona, Delord, Jean-Pierre, Penel, Nicolas, Jalal, Shadia Ibrahim, Xu, Lei, Zeigenfuss, Susan, Pruitt, Scott K., Piha-Paul, Sarina Anne

“…Abstract only…”
Get full text

P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort by Chiappori, Alberto, Thompson, John, Eskens, Fredericus, Spano, Jean-Philippe, Doi, Toshihiko, Hamid, Omid, Diab, Adi, Rizvi, Naiyer, Hu-Lieskovan, Siwen, Ros, Willeke, Thomas, Jacob, Forgie, Alison, Yang, Wenjing, Liao, Ken, Li, Ray, Kazazi, Farhad, Chou, Jeffrey, khoueiry, Anthony El

“…BackgroundPF-04518600 (PF-8600) and utomilumab (uto) are humanized agonist IgG2 monoclonal antibodies for the tumor necrosis factor superfamily receptors OX40…”
Get full text

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers by Diab, Adi, Hamid, Omid, Thompson, John A, Ros, Willeke, Eskens, Ferry A L M, Doi, Toshihiko, Hu-Lieskovan, Siwen, Klempner, Samuel J, Ganguly, Bishu, Fleener, Catherine, Wang, Xiao, Joh, Tenshang, Liao, Ken, Salek-Ardakani, Shahram, Taylor, Carrie Turich, Chou, Jeffrey, El-Khoueiry, Anthony B

“…Stimulation of effector T cells is an appealing immunotherapeutic approach in oncology. OX40 (CD134) is a costimulatory receptor expressed on activated CD4 and…”
Get full text

Abstract CT150: A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1) by Postel-Vinay, Sophie, Lam, Vincent K., Ros, Willeke, Bauer, Todd M., Hansen, Aaron R., Cho, Daniel C., Hodi, F. Stephen, Schellens, Jan H.M., Litton, Jennifer K., Aspeslagh, Sandrine, Autio, Karen A., Opdam, Frans L., McKean, Meredith, Somaiah, Neeta, Champiat, Stephane, Altan, Mehmet, Spreafico, Anna, Rahma, Osama, Paul, Elaine M., Ahlers, Christoph M., Zhou, Helen, Struemper, Herbert, Gorman, Shelby A., Watmuff, Maura, Yablonski, Kaitlin M., Yanamandra, Niranjan, Chisamore, Michael J., Schmidt, Emmett V., Hoos, Axel, Marabelle, Aurélien, Weber, Jeffrey S., Heymach, John V.

“…Abstract Background: OX40 is a costimulatory receptor transiently expressed on the surface of activated T cells and some innate immune cells (e.g. NK cells)…”
Get full text

Abstract CT010: Pharmacodynamic (PD) changes in tumor RNA expression and the peripheral blood T cell receptor (TCR) repertoire in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) by Diab, Adi, Hamid, Omid, Thompson, John A., Ros, Willeke, Eskens, Fredericus A. L. M., Doi, Toshihiko, Hu-Lieskovan, Siwen, Long, Hua, Joh, Tenshang, Potluri, Shoba, Wang, Xiao, Fleener, Catherine, Taylor, Carrie Turich, Ganguli, Bishu J., Chou, Jeffrey, El-Khoueiry, Anthony B.

“…Abstract Introduction: PF-8600 is a fully human IgG2 agonistic mAb against the tumor necrosis factor superfamily receptor OX40. OX40 improves T cell survival,…”
Get full text

Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies by Bang, Yung-Jue, Ueno, Makoto, Malka, David, Chung, Hyun Cheol, Nagrial, Adnan, Kelley, Robin Kate, Piha-Paul, Sarina Anne, Ros, Willeke, Italiano, Antoine, Nakagawa, Kazuhiko, Rugo, Hope S., De Braud, Filippo G., Varga, Andrea I., Hansen, Aaron Richard, Gao, Chao, Krishnan, Suba, Norwood, Kevin, Doi, Toshihiko

“…Abstract only 4079 Background: Antitumor activity with pembro, an anti–PD-1 antibody, has been observed in patients (pts) with advanced/metastatic biliary…”
Get full text

The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) by El-Khoueiry, Anthony B., Hamid, Omid, Thompson, John A., Ros, Willeke, Eskens, Ferry, Doi, Toshihiko, Hu-Lieskovan, Siwen, Chou, Jeffrey, Liao, Ken, Ganguly, Bishu J, Fleener, Catherine, Joh, Tenshang, Diab, Adi

“…Abstract only 3027 Background: PF-8600 is a novel fully human IgG2 agonistic mAb against human OX40, a TNF receptor superfamily member expressed primarily on…”
Get full text

Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP) by Soerensen, Morten Mau, Ros, Willeke, Rodriguez-Ruiz, Maria E., Robbrecht, Debbie, Rohrberg, Kristoffer Staal, Martin-Liberal, Juan, Lassen, Ulrik Niels, Melero Bermejo, Ignacio, Lolkema, Martijn P., Tabernero, Josep, Boetsch, Christophe, Piper-Lepoutre, Hanna, Waldhauer, Inja, Charo, Jehad, Evers, Stefan, Teichgräber, Volker, Schellens, Jan H. M.

“…Abstract only…”
Get full text

Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA CD3 TCB) for the treatment of CEA-expressing solid tumors by Melero, Ignacio, Segal, Neil Howard, Saro Suarez, Jose M., Ros, Willeke, Martinez Garcia, Maria, Calvo, Emiliano, Moreno, Victor, Ponce Aix, Santiago, Marabelle, Aurelien, Cleary, James M., Hurwitz, Herbert, Eder, Joseph Paul, Jamois, Cancize, Belousov, Anton, Bouseida, Said, Sandoval, Federico, Bacac, Marina, Nayak, Tapan K., Karanikas, Vaios, Argiles, Guillem

“…Abstract only 2549 Background: CEA CD3 TCB (RO6958688) targets CEA on tumor cells and is agonistic for CD3e on T cells. In mouse models, CEA CD3 TCB displays…”
Get full text

Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC) by Tabernero, Josep, Melero, Ignacio, Ros, Willeke, Argiles, Guillem, Marabelle, Aurelien, Rodriguez-Ruiz, Maria E., Albanell, Joan, Calvo, Emiliano, Moreno, Victor, Cleary, James M., Eder, Joseph Paul, Karanikas, Vaios, Bouseida, Said, Sandoval, Federico, Sabanes, Daniel, Sreckovic, Sasha, Hurwitz, Herbert, Paz-Ares, Luis G., Saro Suarez, Jose M., Segal, Neil Howard

“…Abstract only 3002 Background: CEA CD3 TCB (RG7802, RO6958688) is a novel T-cell bispecific antibody targeting CEA on tumor cells and CD3 on T cells. In…”
Get full text

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) by Postel-Vinay, Sophie, Lam, Vincent K, Ros, Willeke, Bauer, Todd M, Hansen, Aaron R, Cho, Daniel C, Stephen Hodi, F, Schellens, Jan H M, Litton, Jennifer K, Aspeslagh, Sandrine, Autio, Karen A, Opdam, Frans L, McKean, Meredith, Somaiah, Neeta, Champiat, Stephane, Altan, Mehmet, Spreafico, Anna, Rahma, Osama, Paul, Elaine M, Ahlers, Christoph M, Zhou, Helen, Struemper, Herbert, Gorman, Shelby A, Watmuff, Maura, Yablonski, Kaitlin M, Yanamandra, Niranjan, Chisamore, Michael J, Schmidt, Emmett V, Hoos, Axel, Marabelle, Aurelien, Weber, Jeffrey S, Heymach, John V

“…BackgroundThe phase I first-in-human study ENGAGE-1 evaluated the humanized IgG1 OX40 agonistic monoclonal antibody GSK3174998 alone (Part 1 (P1)) or in…”
Get full text

First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results by Hamid, Omid, Thompson, John A., Diab, Adi, Ros, Willeke, Eskens, Ferry, Bermingham, Candy, Konto, Cyril, Long, Hua, Liao, Ken, Ganguly, Bishu J, Fleener, Catherine, Pleasic-Williams, Susan, Garzone, Pamela D., Patel, Premal H., Joh, Tenshang, Nuyten, Dimitry S. A., El-Khoueiry, Anthony B.

“…Abstract only…”
Get full text